comparemela.com

Page 3 - David Hudesman News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The Role of Vedolizumab and Risankizumab in CD

Anita Afzali, MD, David Hudesman, MD, Millie Long, and Miguel Regueiro, MD, discuss Vedolizumab and Risankizumab as treatments for Crohn’s Disease (CD).

United statesMiguel regueiroDavid hudesmanAnita afzaliCrohns diseaseRisk stratificationBio naïve populationTumor necrosis factor

Efficacy and Safety of Ustekinumab for CD

Efficacy and Safety of Ustekinumab for CD
hcplive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hcplive.com Daily Mail and Mail on Sunday newspapers.

Maia kayalDavid hudesman

Managing Care for IBD Patients Not Responding to Treatment

Experts discuss how to care for Inflammatory Bowel Disease (IBD) patients who are not responding to treatment.

Anita afzaliDavid hudesmanInflammatory bowel diseaseCrohns diseaseUlcerative colitisProactive disease monitoring

Selecting First-Line Treatments for CD

David Hudesman, MD, Miguel Regueiro, MD, and Maia Kayal, MD, offer first line treatment strategies for patients with Crohn’s Disease (CD).

Miguel regueiroMaia kayalDavid hudesmanTheni dCrohns diseaseFirst line agentCombination therapyRisk stratification

Treatment Factors of IBD

Experts discuss treatment options for patients with Inflammatory Bowel Disease (IBD) and clinical factors to consider.

Anita afzaliMaia kayalDavid hudesmanMiguel regueiroInflammatory bowel diseaseCrohns diseaseUlcerative colitisTreatment optionsTherapy impact

vimarsana © 2020. All Rights Reserved.